BTIG reaffirms Buy on Bicara Therapeutics with $39 price target
BTIG kept its Buy rating on Bicara Therapeutics and set a $39 price target, implying 132.4% upside from the October 16 close of $16.78.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to TradingView, BTIG reiterated its Buy recommendation on Bicara Therapeutics shares and set a $39.00 target price. That level implies a 132.4% gain from the $16.78 close on October 16.
The analyst note says the company's ficerafusp alfa shows clearly stronger efficacy and median overall survival in HPV-negative patients than other treatments. Analysts also estimate peak sales of $993 million for the drug in first-line recurrent or metastatic head and neck squamous cell carcinoma.
why it matters
For biotech stocks, research notes like this can shape sentiment around a single name but rarely move the broader market. Investors will likely focus on the company's clinical data and its development plans.
tags
instruments
sources
- BTIG reiterates Buy rating on Bicara Therapeutics, $39 price target — TradingView, 19 October 2026 at 09:56 UTC
- BTIG reiterates Buy rating on Oruka Therapeutics, $151 price target — TradingView, 19 October 2026 at 09:54 UTC
- BTIG reiterates Buy rating on Live Nation Entertainment, $215 price target — TradingView, 19 October 2026 at 10:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗